Evidence map›Paper›PMID 30023514›Full record

ArticleACS omega2017

Identification of a New Function of Cardiovascular Disease Drug 3-Morpholinosydnonimine Hydrochloride as an Amyloid-β Aggregation Inhibitor.

Baiping Ren, Mingzhen Zhang, Rundong Hu, Hong Chen, Manli Wang, Yufeng Lin, Yan Sun, Lingyun Jia, Guizhao Liang, Jie Zheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Baiping RenDepartment of Chemical & Biomolecular Engineering, The University of Akron, Akron, Ohio 44325, United States.
Mingzhen ZhangDepartment of Chemical & Biomolecular Engineering, The University of Akron, Akron, Ohio 44325, United States.
Rundong HuDepartment of Chemical & Biomolecular Engineering, The University of Akron, Akron, Ohio 44325, United States.
Hong ChenDepartment of Chemical & Biomolecular Engineering, The University of Akron, Akron, Ohio 44325, United States.
Manli WangMingyuan Staff-Worker Hospital of Xinjiang Oil Field Company, 789 Youhao Beilu, Urumqi, Xinjiang 830000, China.
Yufeng LinMingyuan Staff-Worker Hospital of Xinjiang Oil Field Company, 789 Youhao Beilu, Urumqi, Xinjiang 830000, China.
Yan SunDepartment of Biochemical Engineering and Key Laboratory of Systems Bioengineering of the Ministry of Education, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.
Lingyun JiaSchool of Life Science and Biotechnology, Dalian University of Technology, Dalian 116024, China.
Guizhao LiangDepartment of Chemical & Biomolecular Engineering, The University of Akron, Akron, Ohio 44325, United States.
Jie ZhengDepartment of Chemical & Biomolecular Engineering, The University of Akron, Akron, Ohio 44325, United States.
University of Akron · USDalian University of Technology · CNTianjin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) and Alzheimer's disease (AD) have a mutual cause-and-effect relationship, and they share some common risk factors. Although numerous Food and Drug Administration (FDA)-approved drugs have been developed for CVD treatment, no drugs are clinically available for AD treatment. Given the common disease-causing factors and links between the two diseases and the well-demonstrated drugs for CVD, we propose to re-examine the new potential of the existing CVD drugs as amyloid-β (Aβ) inhibitors. 3-Morpholinosydnonimine hydrochloride (SIN-1) is an FDA-approved drug for inhibiting platelet aggregation in CVD. Herein, we examine the inhibition activity of SIN-1 on the aggregation and toxicity of Aβ

Identifiers

PMID30023514
PMCPMC6044715
OpenAlexW2580664873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.